Imperial Tobacco Canada: Ban on ZONNIC Nicotine Pouches in Convenience Stores Leads to Cigarette Sales Rebound, Calls for Restoring Multi-Channel Supply

Aug.20.2025
Imperial Tobacco Canada: Ban on ZONNIC Nicotine Pouches in Convenience Stores Leads to Cigarette Sales Rebound, Calls for Restoring Multi-Channel Supply
Imperial Tobacco Canada stated that one year ago, the government removed the nicotine pouch ZONNIC from convenience stores, restricting sales to behind-the-counter in pharmacies. This move caused ZONNIC sales to plummet, cigarette sales to rebound by 2.8%, and was accompanied by a surge of high-dose illegal nicotine pouches and black-market cigarettes (exceeding 500 million packs annually). The company is calling for an evidence-based harm reduction approach to restore multi-channel supply throu

Key Points:

  • Opposite policy effect: After ZONNIC was banned from convenience stores, legal product sales plummeted, while cigarette consumption increased.
  • Black market surge: Illegal nicotine pouches quickly flooded the market, with nicotine levels far above legal limits, easily accessible to both youth and adults.
  • Setback for quitters: In rural and remote areas lacking pharmacy access, adult smokers faced greater obstacles.
  • Pharmacist burden: Significant increase in administrative workload, diverting resources from patient care.
  • Economic blow: Affecting about 200,000 convenience retail jobs nationwide, threatening small businesses that rely on legal nicotine product sales.

 


 

According to Newswire on August 19, Imperial Tobacco Canada announced that one year ago, the Canadian government prohibited the sale of ZONNIC — the only nicotine pouch approved by Health Canada as a smoking cessation product — in convenience stores, allowing sales only behind pharmacy counters. The policy was intended to control nicotine product use and protect public health. However, new data show the measure has had the exact opposite effect.

 

Illegal sales surge: Many unregulated nicotine pouches with nicotine contents far above legal limits are now flooding both the physical market and e-commerce platforms, easily accessible to both youths and adults.

 

Smokers face barriers to quitting: In rural and remote areas where pharmacies are scarce, adult smokers who relied on ZONNIC to quit are now facing unnecessary obstacles.

 

Pharmacists under pressure: Pharmacists play an indispensable role in smoking cessation, but instead of focusing their time on essential patient care, they are now burdened with additional and unnecessary administrative work.

 


 

Over the past year, ZONNIC sales plummeted while cigarette sales increased by 2.8%. At the same time, the illicit market rapidly expanded, with more than 500 million unregulated nicotine pouches entering the market, many containing nicotine far above legal limits, and sold through retailers and online platforms — making them easily available to young people.

 

Eric Gagnon, Vice President of Corporate and Regulatory Affairs at Imperial Tobacco Canada, criticized the policy:

 

“The government cracked down on the country’s only legal, regulated nicotine pouch, but fueled the black market. ZONNIC was never the problem — it was the solution for many smokers.”

 


 

In addition to the rising risks of illegal products, smokers attempting to quit are also heavily impacted. In remote regions with limited pharmacy access, many adults have lost convenient access to ZONNIC. Pharmacists, meanwhile, are burdened with additional administrative tasks, diverting resources away from patient care.

 

On the economic front, the policy has hit the convenience retail sector hard, threatening about 200,000 related jobs nationwide and leaving small businesses dependent on legal nicotine product sales struggling to survive.

 


 

Previously, ZONNIC had been approved by Health Canada as a natural health product and smoking cessation aid, and was endorsed by the Centre for Addiction and Mental Health (CAMH) in Toronto. Data showed that in convenience stores selling ZONNIC, cigarette sales saw double-digit declines, demonstrating its positive effect in helping smokers quit.

 

Imperial Tobacco Canada reiterated its support for the federal government’s goal of reducing the smoking rate to below 5% by 2035, but stressed that this can only be achieved through wider access to innovative cessation tools.

 

Gagnon emphasized:

 

“We are willing to work with Health Canada to ease the burden on pharmacists and help more adults quit smoking for good.”

 

The company urged Canada to adopt evidence-based public health policies to ensure that cessation tools remain conveniently accessible, rather than making the path to quitting smoking more difficult.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24